In 160 transplant-ineligible adults with relapsed/refractory large B-cell lymphoma, CD20-CD19 CAR T-cell therapy zamto-cel lengthened event-free survival vs R-GemOx (median 6·21 vs 2·53 months; HR 0·39). Treatment-related deaths: 3% vs 1%.
RCTn = 160
Borchmann et al. Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study